SEC Comment Letter for LUMOS PHARMA, INC. (CIK 0001126234) — Aug 23, 2022
LUMOS PHARMA, INC. (CIK 0001126234)
Date: Aug. 23, 2022 · CIK: 0001126234 · Accession: 0000000000-22-009068
AI Filing Summary & Sentiment
File numbers found in text: 333-266966
Letter
United States securities and exchange commission logo August 23, 2022 Richard J. Hawkins Chief Executive Officer Lumos Pharma, Inc. 4200 Marathon Blvd #200 Austin, Texas 78756 Re:Lumos Pharma, Inc. Registration Statement on Form S-3 Filed August 19, 2022 File No. 333-266966 Dear Mr. Hawkins: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Margaret Schwartz at 202-551-7153 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Robert Suffoletta, Esq.
Show Raw Text
United States securities and exchange commission logo
August 23, 2022
Richard J. Hawkins
Chief Executive Officer
Lumos Pharma, Inc.
4200 Marathon Blvd #200
Austin, Texas 78756
Re:Lumos Pharma, Inc.
Registration Statement on Form S-3
Filed August 19, 2022
File No. 333-266966
Dear Mr. Hawkins:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Margaret Schwartz at 202-551-7153 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Robert Suffoletta, Esq.